Industry News
Benitec signs license deal with Calando
Californian biopharmaceutical company Calando Pharmaceuticals has granted an exclusive worldwide license to Benitec (ASX:BLT) for the use of its polymeric nucleic acid delivery technology, which Benitec will use in conjunction with its RNA interference (RNAi)-based therapeutic for hepatitis C virus (HCV). [ + ]
Early warning system developed for avian influenza
Victorian Primary Industry researchers have developed a real-time polymerase chain reaction (PCR) test that will become the basis of an early-warning system for avian influenza. [ + ]
In brief: Acrux, CyGenics, Iatia, Psivida
Acrux [ASX: ACR] has announced positive results for a Phase 1 proof-of-concept, pharmacokinetic study of its contraceptive spray Nesterone MDTS. [ + ]
Baker Institute spin-off enters agreement
V-Kardia, the first spin-off company from the Baker Heart Research Institute in Melbourne, has entered into an agreement with Californian-based molecular cardiology company, Celladon, to develop and supply its V-Focus device for percutaneous delivery of gene therapy for congestive heart failure. [ + ]
Taskforce to advise government on investment in medical research
The federal government has set up the Private Sector Investment Taskforce to come up with strategies to gain more support for Australian researchers from business and philanthropic funds, both in Australia and overseas. [ + ]
Agenix's Thromboview found safe
Brisbane Agenix (ASX:AGX, OTC(NASDAQ):AGXLY) has found that its Thromboview blood clot diagnostic is safe and not associated with an immune response, according to results from its Phase Ib deep vein thrombosis (DVT) study. [ + ]
Study findings a no-brainer
A study has shown that brain shrinkage occurs only in ageing men, although cognitive performance remains constant. [ + ]
Brain shrinkage not related to memory capacity
Brain shrinkage, a common symptom of ageing when people enter their 60s, appears to have no impact on an individual’s capacity of thinking or learning, according to a research conducted by Australian National University (NAU) scientists, calling for a revision on the long-standing views about the influence of aging on the brain.
[ + ]Young cancer researchers recognised
Cure Cancer Australia has announced the winners of its 2005 young researcher awards, which recognise outstanding cancer researchers in the early stages of their career. [ + ]
Mayne Group to demerge with new chairmen
Australian healthcare company, Mayne Group, will proceed with the demerger of its global injectable pharmaceutical business, Mayne Pharma, and its domestic healthcare businesses, Mayne Diagnostic Services, Mayne Pharmacy, and Mayne Consumer Products. [ + ]
New diagnostic for airborne allergens
A new technique that better identifies asthma and allergy triggers may soon provide some welcome relief to susceptible individuals. [ + ]
Bionomic's epilepsy diagnostic receives positive feedback
Thebarton (SA) epilepsy specialist Bionomics (ASX:BNO, BNOOA; US OTC:BMICY) is getting positive feedback on its newly commercialised DNA diagnostic for severe myoclonic epilepsy of infancy (SMEI). [ + ]
Discovery time recommended in dispute between Ventracor and Heartware
An initial recommendation has been made in the patent infringement dispute between Sydney artificial heart firms Ventracor (ASX:VCR) and Heartware (ASX:HTW). [ + ]
Prana CEO resigns, PBT-2 development to continue
Dr Jonas Alsenas has resigned as CEO and director of Melbourne based Prana Biotechnology (ASX:PBT; NASDAQ:PRAN), with Geoffrey Kempler re-assuming the joint positions of executive chairman and CEO. [ + ]
Committee for Melbourne report calls for action
Victoria won't meet its objective of becoming a top five global biotech location by 2010 if Victorian biotech companies fail to attract expansion capital, according to a report released today by the Committee for Melbourne (CfM). [ + ]